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patients with central and lateral LNM (P< 0.001, P¼ 0.007). The Ct
value was the only independent factor to predict central LNM (OR 0.918,
P¼ 0.025). The area under the ROC curve (AUC) for diagnosing central
lence has been observe
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Abstract: Papillary thyroid microcarcinoma (PTMC) usually has
excellent prognosis, but a small subset shows aggressive behavior.
Although the B-Raf proto-oncogene, serine/threonine kinase
(BRAF)V600E mutation is the most common oncogenic alteration in
PTMCs, it is frequently heterogeneously distributed within tumors. The
aim of this study was to investigate the association of the BRAFV600E
mutation found in fine needle aspirates from PTMCs with known
clinicopathologic prognostic factors, based on both its presence and
a quantitative approach that uses cycle threshold (Ct) values obtained by
a real-time PCR technique.
The 460 PTMC patients were included, with 367 patients having the
BRAFV600E mutation. Clinicopathologic variables were compared
between patients with and without the BRAFV600E mutation.
BRAFV600E Ct values were compared according to clinicopathologic
prognostic factors. Multivariate analyses were performed to evaluate
factors predicting extrathyroidal extension and central and lateral lymph
node metastasis (LNM). Each analysis used either the BRAFV600E
mutation status or the Ct value as an independent variable for all the
study patients and the 367 BRAFV600E-positive patients. Receiver-
operating characteristic (ROC) curve analysis was performed to evalu-
ate the diagnostic performance of BRAFV600E Ct values in predicting
central and lateral LNM.
TheBRAFV600Emutation statuswas not associatedwith clinicopatho-
logic prognostic factors among the 460 PTMC patients. Of the 367
BRAFV600E-positive patients, Ct values were significantly lower inye Sun Lee, MS, n, MD, PhD,
n Young Kwak, MD, PhD
LNMwas 0.623 (sensitivity, 50.0%; specificity, 71.9%) and for diagnos-
ing lateral LNM, it was 0.796 (sensitivity, 71.4%; specificity, 94.7%).
In conclusion, real-time PCR Ct values for the BRAFV600E mutation
obtained fromfine needle aspirates can be associated with central LNM in
PTMC patients. Although BRAFV600E Ct values did not reach statistical
significance for predicting lateral LNM in our study, further validation
through larger studies can be used to overcome any possible type-II errors.
With further studies, Ct values for theBRAFV600Emutation obtained from
fine needle aspirates may have important implications for predicting both
central and lateral LNM in patients with PTMCs.
(Medicine 94(28):e1149)
Abbreviations: AUC = area under the ROC curve, CIs =
confidence intervals, Ct = cycle threshold, LNM = lymph node
metastasis, LN = lymph node, ORs = odds ratios, PCR =
polymerase chain reaction, PTC = papillary thyroid carcinoma,
PTMC = papillary thyroid microcarcinoma, ROC = receiver-
operating characteristic, US = ultrasonography, US-FNA = US-
guided fine-needle aspiration.
INTRODUCTION
P apillary thyroid carcinoma (PTC) accounts for approxi-mately 90% of thyroid malignancies, with an increasing
number of small thyroid cancers recently being detected due to
the widespread use of ultrasonography (US) and US-guided
fine-needle aspiration (US-FNA).1,2 Papillary thyroid micro-
carcinoma (PTMC) is defined as PTC that measures10mm in
its greatest dimension, and the majority of PTMCs are indolent
cancers that show favorable prognosis.3 Although various
guidelines currently do not recommend FNA for subcentimeter
nodules detected in patients without high-risk clinical features,
the incidence of PTMC is increasing globally, from 6.1% to
29% of all thyroid cancers to 21.7% to 47%.2,4,5 However, a
small but significant portion of PTMCs show aggressive beha-
vior, with a 3.3% average rate of recurrence and a 0.5%
mortality rate from PTMC.3,5,6 Thus, this aggressive subset
would benefit from adjunctive tools that would enable its
differentiation from the vast majority of indolent PTMCs.
The B-Raf proto-oncogene, serine/threonine kinase
(BRAF) mutation is the most common oncogenic alteration
detected in patients with PTC, with more than 90% character-
ized by the change of valine to glutamic acid at codon 600, a
mutation designated as BRAFV600E.7 Its reported incidence
varies from 28.2% to 95.2% of PTMCs, and a greater preva-d in the Korean population.8–10 Research
clinicopathologic prognostic factors of
onflicting results regarding bilaterality,
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multifocality, extrathyroidal invasion, and lymph node metas-
tasis (LNM), in which studies were based on the presence or
absence of the BRAFV600E mutation and did not contain
quantitative information.8,10–13 Clonal BRAFV600E mutation
is a rare occurrence and PTCs frequently consist of a mixture of
tumor cells with wild-type and mutant BRAF.14,15 To address
this topic, quantitative measurements of the BRAFV600E
mutation from surgically resected PTC specimens have been
utilized and the BRAFV600E mutation has been associated with
tumor size, extrathyroidal invasion, and disease recurrence.16–
18 However, to our knowledge, there has been no published
study utilizing BRAFV600E mutation testing in fine needle
aspirates and none quantitatively analyzing the BRAFV600E
mutation in PTMC.
Therefore, the aim of this study was to investigate the
association between the BRAFV600E mutation found in fine
needle aspirates of PTMCs and known clinicopathologic prog-
nostic factors in a BRAFV600E-prevalent population, based on
both the presence of the BRAFV600E mutation and a quantitative
approach that uses cycle threshold (Ct) values obtained by a
highly sensitive real-time polymerase chain reaction (PCR)
technique.
MATERIAL AND METHODS
Study Population
This study was approved by our institutional review board,
and the requirement to obtain informed consent was waived.
Between January 2011 and July 2012, 2390 patients were
confirmed to have PTMC. Among them, 460 patients under-
went US-FNA with simultaneous BRAFV600E mutation testing
using real-time PCR at our institution (a referral center). A total
of 369 women (median age, 49 years; range, 19–76 years) and
91 men (median age, 43 years; range, 24–73 years) were
included. Of them, 367 patients had the BRAFV600E mutation
confirmed through real-time PCR testing from fine needle
aspirates. Twelve and 17 nodules were previously included
in 2 prior studies, respectively. One study focused on the
diagnostic performances of cytology, US, and BRAFV600E
mutation testing, and the other study focused on the additional
value of the BRAFV600E mutation analysis in thyroid nodules
with ‘‘suspicious for malignant’’ cytology-lacking suspicious
US features.7,19
US-FNA and the BRAFV600E Mutation Analysis
At our institution, US-FNA was performed with a 23-
gauge needle attached to a 2-mL disposable plastic syringe
using the freehand technique. FNAs were performed on either
thyroid nodules with suspicious US features or the largest
nodule if there were no suspicious US features. Each lesion
was aspirated at least twice. Materials obtained from the
aspiration biopsy were expelled onto glass slides and smeared.
The material remaining in the syringe after cytological prep-
aration was collected for the BRAFV600E mutation analysis,
which was performed at the request of the referring physician.
Real-time PCR was performed using the Applied Biosys-
tems 7500 real-time PCR system (Applied Biosystems, Foster
City, CA) under the following cycle conditions; denaturation at
508C for 2 minutes (1 cycle), 958C for 10 minutes (1 cycle), and
958C for 15 seconds (1 cycle), followed by one step of annealing
Park et aland elongation at 628C for 45 seconds (40 cycles). A Real-Q
BRAFV600E Detection Kit (BioSewoom, Korea) was used for
the PCR reactions. This is a ready-to-use kit that detects the
2 | www.md-journal.comBRAFV600E (1799T>A) somatic mutation in the BRAF onco-
gene in a background of wild-type genomic DNA using a
multiplex real-time PCR assay based on the TaqMan MGB
probe system. BRAFV600E amplification was detected by
measuring the VIC fluorescence in the AB 7500 system. The
internal control assay, labeled with 6-Carboxyfluorescein, was
used to check for nucleic acid isolation and possible PCR
inhibition. A region of exon 8 of the BRAF gene was used
for amplification as the internal control. The 242 base pairs of
the partial BRAF gene containing the V600E region was
amplified from the human melanoma cell line, SK-MEL-28
(ATCC, Manassas, VA) with the BRAFV600E mutation, and was
inserted into the pZEM-T Easy Vector (Promega, Madison, WI)
to produce the BRAFV600E plasmid DNA. Analytical sensitivity
was evaluated using the BRAFV600E mutation plasmid clone
and the 95% positive cut-off value (limit of detection) was
calculated as 21.5 copy/mL by Probit analysis.20
The Ct was defined as the number of amplification cycles
at which the level of fluorescent signal exceeded the threshold
for the presence of the BRAF mutation. The cut-off value for a
BRAFV600E mutation-positive result was set to Ct 40, according
to our previous research.20 This cut-off value was determined
based on the average Ct value found through 100 repeats of low-
positive concentrations of the BRAFV600E plasmid DNA, for
which a positive rate of 100% was achieved. The Ct value was
determined from a log-linear plot of the PCR signal versus the
cycle number, and was inversely related to the BRAFV600E
mRNA level. Thus, a low Ct value corresponds to a higher
mRNA level.16,21
Surgical Procedure
Total or near-total thyroidectomy was performed in
patients who were either diagnosed or suspected of having
multiple or bilateral tumors, extrathyroidal invasion or LNM
based on preoperative assessment or intraoperative findings.
Regardless of findings on physical examination or preoperative
staging US, all patients underwent routine central compartment
neck dissection including removal of the paratracheal, pretra-
cheal, and prelaryngeal lymph nodes (LNs). Bilateral or ipsi-
lateral central compartment neck dissection was each performed
in patients who underwent total or near-total thyroidectomy or
in those who underwent hemithyroidectomy, respectively. Lat-
eral compartment neck dissection was selectively performed in
patients diagnosed preoperatively as having lateral LNM by
US-FNA. Intraoperative frozen biopsy was performed for LNs
suspicious for metastases detected during surgery, but which
were not found on preoperative staging US. If metastasis was
confirmed, lateral compartments including levels 2, 3, 4 and
anterior 5 were dissected.22,23
Of the 460 PTMC patients, 227 (49.3 %) patients under-
went total or near-total thyroidectomy, 50 (10.9%) patients
underwent subtotal thyroidectomy, and 183 (39.8%) patients
underwent hemithyroidectomy. We evaluated tumor size, mul-
tifocality including both uni-and bilateral tumor foci, extrathyr-
oidal extension, and presence of central and lateral LNM based
on final surgical pathology reports.
Statistical Analysis
Clinicopathologic characteristics of patients with and
without the BRAFV600E mutation were compared with the x2
Medicine  Volume 94, Number 28, July 2015test or Fisher exact test for categorical variables and the Mann–
Whitney U test for continuous variables. Multivariate logistic
regression analysis was used to evaluate independent factors for
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
extrathyroidal extension and central and lateral LNM including
the BRAFV600E mutation status, that is, the presence or absence
of the BRAFV600E mutation was analyzed as an independent
variable.
For the 367 BRAFV600E-positive patients, BRAFV600E Ct
values were compared according to clinicopathologic prognos-
tic factors using the Mann–Whitney U test. The Spearman
correlation coefficient (r) was used to evaluate the association
between the BRAFV600E Ct values and continuous clinicopatho-
logic variables (tumor size, patient age). We performed a
separate multivariate logistic regression analysis to determine
independent factors for extrathyroidal extension and central and
lateral LNM. Odds ratios (ORs) with 95% confidence intervals
(CIs) were calculated after the adjustment of all clinicopatho-
logic factors. In addition, receiver-operating characteristic
(ROC) curve analysis was performed to evaluate the diagnostic
performance of BRAFV600E Ct values in the prediction of
central and lateral LNM.
A 2-tailed P value of less than 0.05 was defined as a
statistically significant difference. Statistical analysis was per-
formed with SPSS for Windows, version 20.0 (IBM Corpor-
Medicine  Volume 94, Number 28, July 2015ation, Armonk, NY) for all data analyses except the ROC curve
analysis which was performed with SAS software (version 9.2,
SAS Inc., Cary, NC).
RESULTS
Themedian tumor size was 6mm (range, 2–10mm) for the
460 PTMCs (Table 1). We analyzed the association between the
BRAFV600E mutation status and variable clinicopathologic
factors in the 460 PTMC patients who underwent BRAFV600E
mutation testing with real-time PCR. The BRAFV600E mutation
was detected in 79.8% (367/460) of the patients from preo-
perative fine needle aspirates. BRAFV6006E-positive patients
were significantly older in age (P¼ 0.008), but none of the other
clinicopathologic prognostic factors showed a significant differ-
ence between patients with and without the BRAFV600E
mutation (Table 1). On multivariate analysis, the BRAFV600E
TABLE 1. Clinicopathologic Characteristics and the BRAFV600E Mu
BRAFV600Eþ (n¼ 367)
Age, year, median (range) 47 (19–76)
Sex
Female 289 (78.7%)
Male 78 (21.3%)
Size, mm, median (range) 6 (2–10)
Central LNM
Positive 114 (31.1%)
Negative 253 (68.9%)
Lateral LNM
Positive 7 (1.9%)
Negative 360 (98.1%)
Extrathyroidal extension
Positive 148 (40.3%)
Negative 219 (59.7%)
Multifocality
Positive 93 (25.3%)
Negative 274 (74.7%)
BRAFV600Eþ¼BRAFV600E mutation-positive, BRAFV600E¼BRAFV60
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.mutation status was not significantly associated with any of the
clinicopathologic prognostic factors (Table 2). Extrathyroidal
extension was significantly associated with older age (OR
1.024, 95% CI 1.006–1.043, P¼ 0.011), female sex (OR
1.708, 95% CI 1.012–2.883, P¼ 0.045), and larger tumor size
(OR 1.275, 95% CI 1.159–1.404, P< 0.001). Central LNMwas
significantly associated with younger age (OR 0.957, 95% CI
0.937–0.976, P< 0.001), larger tumor size (OR 1.152, 95% CI
1.039–1.279, P¼ 0.008), and multifocality (OR 1.649, 95% CI
1.021–2.665, P¼ 0.041). Lateral LNM did not show a signifi-
cant association with any of the clinicopathologic-risk factors.
For the 367 PTMC patients with the BRAFV600E mutation
found through FNA, the association between Ct values of the
BRAFV600E mutation and variable clinicopathologic factors
was analyzed. On univariate analysis, the quantitative expres-
sion of the BRAFV600E mutation, expressed as a Ct value, was
significantly lower in patients with central and lateral LNM
(P< 0.001 and P¼ 0.007, respectively), but there was no
significant difference according to sex, extrathyroidal exten-
sion, and multifocality (Table 3). BRAFV600E Ct values were
negatively correlated with tumor size, showing a weak but
significant negative association (r¼0.306, P¼ < 0.001).
There was no significant association between BRAFV600E Ct
values and patient age (r¼ 0.022, P¼ 0.671). On multivariate
analysis, the BRAFV600E Ct value was the only independent
factor to predict central LNM (OR 0.918, 95% CI 0.853–0.989,
P¼ 0.025 (Table 4). Extrathyroidal extension was significantly
associated with older age (OR 1.029, 95% CI 1.008–1.050,
P¼ 0.006) and larger tumor size (OR 1.269, 95% CI 1.133–
1.420, P< 0.001). Central LNM was also significantly associ-
ated with younger age (OR 0.963, 95% CI 0.942–0.985,
P¼ 0.001) and larger tumor size (OR 1.139, 95% CI 1.011–
1.282, P¼ 0.033). Lateral LNM did not show a significant
association with any of the clinicopathologic-risk factors in
the 367 BRAFV600E-positive PTMC patients (P¼ 0.111).
Cycle Threshold Value for BRAF in PTMCThe area under the ROC curve (AUC) for distinguishing
central LNM from noncentral LNM groups was 0.623 (95% CI
0.559–0.687, P< 0.001) at a BRAFV600E Ct cut-off value of
tation Status in 460 Papillary Thyroid Microcarcinoma Patients
BRAFV600E (n¼ 93) P Value
51 (24–76) 0.008
0.868
80 (86.0%)
13 (14.0%)
6 (2–10) 0.969
0.140
21 (22.6%)
72 (77.4%)
0.332
4 (4.3%)
89 (95.7%)
0.868
36 (38.7%)
57 (61.3%)
0.395
19 (20.4%)
74 (79.6%)
0E mutation-negative, LNM¼ lymph node metastasis.
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TABLE 2. Multivariate Logistic Regression Analysis for Clinicopathologic Factors Based on the Presence or Absence of the
BRAFV600E Mutation in 460 Papillary Thyroid Microcarcinoma Patients
Dependent Variable
Extrathyroidal Extension Central LNM Lateral LNM
Variables OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value
Age 1.024 (1.006–1.043) 0.011 0.957 (0.937–0.976) <0.001 0.964 (0.908–1.023) 0.229
Female sex 1.708 (1.012–2.883) 0.045 0.601(0.360–1.005) 0.052 2.735 (0.328–22.773) 0.352
Size, mm 1.275 (1.159–1.404) <0.001 1.152 (1.039–1.279) 0.008 1.230 (0.901–1.680) 0.192
BRAFV600Eþ 1.231 (0.737–1.995) 0.447 1.357 (0.769–2.394) 0.292 0.312 (0.082–1.179) 0.086
Central LNM 1.505 (0.960–2.359) 0.075 3.087 (0.802–11.881) 0.101
Lateral LNM 2.108 (0.572–7.763) 0.262 3.358 (0.869–12.985) 0.079
Extrathyroidal Extension 1.514 (0.968–2.370) 0.069 2.046 (0.544–7.697) 0.290
Multifocality 0.725 (0.454–1.159) 0.179 1.649 (1.021–2.665) 0.041 2.525 (0.707–9.023) 0.154
al,
Park et al Medicine  Volume 94, Number 28, July 201528.01 (sensitivity, 50.0%; specificity, 71.9%) (Figure 1A). The
AUC for distinguishing lateral LNM from nonlateral LNM
groups was 0.796 (95% CI 0.547–1, P¼ 0.02) at a BRAFV600E
Ct cut-off value of 25.26 (sensitivity, 71.4%; specificity, 94.7%)
(Figure 1B).
DISCUSSION
We found that the Ct value of the BRAFV600E mutation
was an independent factor for predicting central LNM in
patients with PTMCs in a BRAFV600E-prevalent population.
Because a lower Ct value corresponds to a higher BRAFV600E
mRNA level, we can assume that a negative association
between Ct values and central LNM indicates a positive associ-
BRAFV600Eþ¼BRAFV600E mutation-positive, CI¼ confidence intervation with the quantitative expression of the BRAFV600E
mutation. Thus, a larger amount of RNA with the BRAFV600E
mutation expressed is associated with central LNM.16,24 Our
TABLE 3. Clinicopathologic Characteristics and Quantitative
Expression of the BRAFV600E Mutation in 367 BRAFV600E-
Positive Papillary Thyroid Microcarcinoma Patients
BRAFV600E Ct Value P Value
Sex 0.181
Female 29.3 (23.4–39.8)
Male 29.1 (24.0–37.5)
Central LNM <0.001
Positive 28.0 (23.4–37.3)
Negative 29.6 (23.4–39.8)
Lateral LNM 0.007
Positive 25.1 (24.0–35.4)
Negative 29.2 (23.4–39.8)
Extrathyroidal extension 0.063
Positive 28.6 (23.4–39.8)
Negative 29.6 (24.2–38.1)
Multifocality 0.062
Positive 28.4 (24.2–37.8)
Negative 29.3 (23.4–39.8)
BRAFV600E Ct values are expressed as median and range in par-
entheses. Ct¼ cycle threshold, LNM¼ lymph node metastasis.
4 | www.md-journal.comresults are the first to show that the Ct value, a quantitative
measurement of the BRAFV600E mutation, may be beneficial in
the preoperative risk stratification of PTMC patients.
Although the association between the presence of the
BRAFV600E mutation and clinicopathologic prognostic factors
of PTC has been extensively researched in the last decade,
studies both on PTC and PTMC have shown variable results.10–
13,25,26 In PTMC, the BRAFV600E mutation has been associated
with central and/or lateral LNM, multifocality, extrathyroidal
invasion, and advanced tumor stage.8,11,12,25,26 However, other
studies have reported the presence of the BRAFV600E mutation
in a significant percentage of PTMC patients without a signifi-
cant association with poor prognostic factors.10,13 Such variable
results have been similarly reported in Korean PTC patients,
who have a much higher prevalence of the BRAFV600E mutation
than patients of different ethnicities and who live in an iodine-
sufficient area.10,16,26,27 The controversial relationship between
the presence of the BRAFV600E mutation and prognostic factors
representing tumor aggressiveness has been recently considered
to be partly due to the heterogeneous distribution of the
BRAFV600E mutation within tumors.14,15,17,18,28 Furthermore,
false-positive results for the BRAFV600E mutation have been
reported, especially when using highly sensitive analytic
methods such as real-time PCR, and this may have contributed
to such controversial results. Although a Ct cut-off value of 40
was reported to have a positive rate of 100% in our institution,
nodules with Ct values ranging from 40 to 32.4 in this studymay
also include false-positives as the Ct cut-off value showing a
specificity of 100% was 32.4.20 In this study, the BRAFV600E
mutation showed no significant association with variable clin-
icopathologic factors when qualitatively detected, which is
consistent with several studies which have shown no association
between the BRAFV600E mutation status and prognostic factors
for PTMC.10,13
Although Ct values were significantly lower in patients
with lateral LNM, there was no significant association between
Ct values and lateral LNM at multivariate analysis (P¼ 0.111).
However, at ROC curve analysis of BRAFV600E Ct values, the
AUC for distinguishing patients with lateral LNM from those
without lateral LNM was larger than that for distinguishing
LNM¼ lymph node metastasis, OR¼ odds ratio.central LNM and noncentral LNM groups, with both higher
sensitivity and specificity. These results may imply that
whereas an association between BRAFV600E Ct values and
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 4. Multivariate Logistic Regression Analysis for Clinicopathologic Factors Based on the Quantitative Expression of the
BRAFV600E Mutation in 367 BRAFV600E-Positive Papillary Thyroid Microcarcinoma Patients
Dependent Variable
Extrathyroidal Extension Central LNM Lateral LNM
Variables OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value
Age 1.029 (1.008–1.050) 0.006 0.963 (0.942–0.985) 0.001 0.961 (0.892–1.035) 0.297
Female sex 1.579 (0.896–2.783) 0.114 0.639 (0.366–1.116) 0.116 1.859 (0.204–16.935) 0.582
Size, mm 1.269 (1.133–1.420) <0.001 1.139 (1.011–1.282) 0.033 1.191 (0.777–1.824) 0.423
BRAFV600E Ct value 0.983 (0.918–1.052) 0.620 0.918 (0.853–0.989) 0.025 0.756 (0.536–1.066) 0.111
Central LNM 1.317 (0.801–2.166) 0.277 2.960 (0.508–17.258) 0.228
Lateral LNM 2.832 (0.507–15.815) 0.235 3.163 (0.552–18.135) 0.316
Extrathyroidal extension 1.326 (0.809–2.172) 0.264 2.424 (0.419–14.012) 0.323
Multifocality 0.720 (0.428–1.211) 0.215 1.357 (0.796–2.315) 0.262 1.527 (0.298–7.838) 0.612
eta
Medicine  Volume 94, Number 28, July 2015 Cycle Threshold Value for BRAF in PTMCcentral LNM was identified in our study due to the sufficient
number of events (n¼ 114), a possible association with lateral
LNM may not have been identified with multivariate analysis
due to the small number of lateral LNM events (n¼ 7). Further
studies with a larger number of lateral LNM events are needed
to evaluate the association between BRAFV600E Ct values and
lateral LNM in PTMC patients.
Previous reports based on surgical specimens showed no
significant association between the allelic percentage of the
BRAFV600E mutation and LNM in patients with PTC.17,18,28
This may be attributed to differences in the study population,
which showed more heterogeneity in tumor size and patient
management. The mean tumor volume or tumor size varied
from 14.9mL and 2.2 cm and 80% of the patients underwent
central neck dissection, with no relevant information presented
in 1 study.17,18,28 These results that contrasted with our own
suggest that the association between quantitative measurements
of the BRAFV600E mutation and LNM are more prominent or
limited to small tumors such as microcarcinomas. Furthermore,
microcarcinomas have been shown to be more heterogeneous
with respect to the BRAFV600E mutation when compared with
larger tumors, and thus a quantitative expression of the
BRAFV600E mutation may be a more useful prognostic factor
in this subgroup.15 In addition, because of the relatively high
prevalence of the BRAFV600E mutation in PTMCs (79.8%, 367
of 460), identifying an association between the quantitative
expression of the BRAFV600E mutation and LNM may have
been easier in our study population.
A high percentage of BRAFV600E alleles has been associ-
ated with larger tumor size, extrathyroidal extension, or recur-
rence in PTC, but previous studies were based on surgically
resected tumor specimens and thus were not applicable in
preoperative clinical settings.17,18 In this study, the BRAFV600E
Ct values were significantly correlated with tumor size in
PTMCs, similar to previous studies that analyzed the percentage
of mutant BRAFV600E alleles or its relative expression in
PTC.16–18
The role of routine prophylactic central LN dissection in
the treatment of PTMC remains controversial. Currently, the
American Thyroid Association only recommends central LN
CI¼ confidence interval, Ct¼ cycle threshold, LNM¼ lymph node mdissection in clinically involved neck LNs or in T3 or T4
tumors, and some authors suggest that prophylactic central
LN dissection may increase the risk of complications and
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.overall morbidity without improvement in survival.29,30 How-
ever, subclinical central LNM is frequent in PTMC and pro-
phylactic central LN dissection may reduce short-term
locoregional recurrence.31 Therefore, a more selective approach
in the use of prophylactic central LN dissection may be more
reasonable to avoid the minimal potential for morbidity.32
Because US shows low sensitivity in identifying central
LNM, researchers have strived to find preoperative predictive
factors for central LNM.22,33,34 With further validation with
large sample studies, our results may also aid in the preoperative
decision-making regarding surgical treatment.
Our study had several limitations. First, this was a retro-
spective study, and we included patients who underwent FNA
and additional BRAFV600E testing. Therefore, some selection
bias is inevitable. Second, although the Ct value quantitatively
reflects gene expression in real-time PCR, it is determined from
a log-linear plot of the PCR signal versus the cycle number and
thus, is not a linear term.21 For accurate relative quantification
of real-time PCR data, comparisons relative to a reference gene
are required. However, in real clinical practice, the routine
acquisition of such data is both impractical and impossible.
Furthermore, studies in other fields have directly utilized the Ct
value as a relative measure of mRNA concentration levels.24,35
As real-time PCR is increasingly used in the detection of the
BRAFV600E mutation, our study demonstrates the possibility of
utilizing a quantitative value which is easily attainable in actual
clinical practice. Another limitation of our study was that the
BRAFV600E mutation analysis was performed with fine needle
aspirates, and we did not evaluate possible contamination by
nonthyroid cells such as lymphocytes. However, our study has
clinical value in that it investigates the actual potential use of
BRAFV600E Ct values in preoperative decision-making for
PTMC patients. Also, because only PTMCs were included,
the majority of the tumor volume was more likely to be included
when performing US-FNAwith the freehand technique. Finally,
Ct values were not statistically significant independent predic-
tors of lateral LNM at multivariate analysis, even though the
AUC for distinguishing patients with lateral LNM from those
without lateral LNM was higher than that for distinguishing
central LNM and noncentral LNM groups. Statistically, the
stasis, OR¼ odds ratio.limited number of lateral LNM cases may have resulted in a
type-II error, which means that significant differences were not
detected even with true differences existing between the groups.
www.md-journal.com | 5
for the BRAFV600E mutation obtained from fine needle aspirates
Mutation Analysis: BRAF V600E Is Acquired Early During Tumor
FIGURE 1. ROC curves of BRAFV600E Ct values to distinguish
patients with lymph node metastasis from patients without lymph
node metastasis. (A) The use of a cut-off value of 28.01 revealed an
area under the ROC curve (AUC) of 0.623 (95% CI 0.559–0.687)
for the detection of central lymph node metastasis. (B) The use of a
Park et alTherefore, further studies are needed to evaluate the real
association between BRAFV600E Ct values and lateral LNM
in PTMC patients with a larger number of events.
In summary, this study demonstrates that real-time PCR Ct
values for the BRAFV600E mutation obtained from fine needle
cut-off value of 25.26 revealed an AUC of 0.796 (95% CI 0.547–1)
for the detection of lateral lymph node metastasis. CI¼ confidence
interval, Ct¼ cycle threshold, ROC¼ receiver-operating charac-
teristic.aspirates can be associated with central LNM in PTMC patients.
Although BRAFV600E Ct values did not reach statistical sig-
nificance for predicting lateral LNM in our study, further
6 | www.md-journal.comvalidation through larger studies can be used to overcome
any possible type-II errors. With more research, PCR Ct values
Medicine  Volume 94, Number 28, July 2015may have important implications for predicting both central and
lateral LNM in patients with PTMCs.
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